NCT01785472

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension

A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Patients With Essential Hypertension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,438 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the efficacy and safety of multiple doses of LCZ696 compared to olmesartan in Asian patients with essential hypertension

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	LCZ696	LCZ696 200 mg tablet
DRUG	Olmesartan	Olmesartan 20 mg capsule
DRUG	Placebo of LCZ696	Placebo tablet of LCZ696 200 mg once daily
DRUG	Placebo of Olmesartan	Placebo capsule of olmesartan 20 mg once daily

Timeline

• Start date: 2013-04-01
• Primary completion: 2014-08-01
• Completion: 2014-08-01
• First posted: 2013-02-07
• Last updated: 2016-12-29
• Results posted: 2015-09-04

Locations

50 sites across 7 countries: China, Hong Kong, Philippines, Singapore, South Korea, Taiwan, Thailand